Intradermal Trivalent Influenza Vaccine With Imiquimod

Chronic Illness Clinical Trial

Official title:

Efficacy and Effectiveness of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod, a Double Blind Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01508884
• Other study ID #: HKU-2012-432
• Status: Completed
• Phase: N/A
• First received: January 9, 2012
• Last updated: December 8, 2013
• Start date: January 2012
• Est. completion date: December 2012

Study information

• Verified date: December 2013
• Source: The University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hong Kong: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Despite the WHO International Health Regulations Emergency Committee declared an end to the 2009 H1N1 pandemic globally, the emergence of the novel 2009 H1N1 virus in March 2009 has affected more than 214 countries with at least 18000 deaths [1]. Patients with chronic underlying illness and extreme of ages are at risk of developing severe disease and complications [2-3]. Resistance to oseltamivir has also been reported [4]. Therefore, vaccination with the 2010/2011 trivalent influenza vaccine (TIV) with the 2009 H1N1-like virus incorporated will be the best protection against the influenza infection, especially among the at risk population. Recent study on dose sparing seasonal influenza vaccine delivered via a novel intradermal microneedle has demonstrated good immunogenic responses similar to full-dose intramuscular vaccination [6]. Poor immunogenicity of the H1N1 2009 component of the trivalent influenza has been reported [7].

Study has also suggested the combined intradermal vaccination with local stimulation of dermal antigen presenting cells by applying imiquimod cream (Aldara) to the injection site, which activate antigen presenting cells (APC) through the toll-like receptor 7 (TLR7) may produce better immunogenicity [8].

Imiquimod cream is currently registered for the treatment of warts and basal cell carcinoma. Scientific evidence has demonstrated that after treatment with imiquimod, the antigen is processed and presented to cells of the adaptive immune system leading to clearance of the virus and subsequent clearance of the lesions [9]. In addition to functional maturation, imiquimod induces migration of dendritic cells from the dermis to draining lymph nodes [10,11]. Subcutaneous administration of imiquimod as vaccine adjuvant simultaneously with the antigen of interest, has shown to induce enhanced responses towards the administered antigen [12].

We therefore performed a prospective, double blind, randomized controlled study to compare the safety and immunogenicity between intradermal 2011/2012 TIV immunization with pretreatment of imiquimod cream and conventional full dose intramuscular 2011/2012 TIV immunization with pretreatment of aqueous cream as control.

Description:

References

1. World Health Organization. Influenza A (H1N1) - update 95 [cited 2010 April 10]. Available from http://www.who.int/csr/don/2009_12_30/en/index.html

2. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374: 2072-9.

3. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896-902.

4. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.

5. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 2009;15:1970-2.

6. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009;27:454-9

7. Myers CA, Faix DJ, Blair PJ. Possible reduced effectiveness of the 2009 H1N1 component of live, attenuated influenza vaccine. Clin Infect Dis. 2011;15;53:207-8.9.

8. Roukens R, Vossen AC, Boland GJ, et al. Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). Vaccine 2010;4288-4293.

9. Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod, an international update on therapeutic uses in dermatology. Int J Dermatol 2002;41(11):810-6.

10. Burns Jr RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000;94(1):13-23.

11. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114(1):135-41.

12. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004;22(13-14):1799-809.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• All adult patients at the age of 21 or above with chronic illness and given written informed consent

• Subjects must be available to complete the study and comply with study procedures. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.

Exclusion Criteria:

• Clinically significant immune-related diseases or significant recent co-morbidities

• Inability to comprehend and to follow all required study procedures

• History or any illness that might interfere with the results of the study or pose additional risk to the subjects due to participation in the study

• Have received 2011/2012 TIV

• Have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination.

• Have a known allergy to eggs or other components of the Study Vaccines (including gelatin, formaldehyde, octoxinol, thimerosal, and chicken protein), or history of any anaphylaxis, serious vaccine reactions, to any excipients.

• Have a positive urine or serum pregnancy test within 24 hours prior to vaccination, or women who are breastfeeding.

• Female of childbearing potential, not using any acceptable contraceptive methods for at least 2 months prior to study entry or that do not plan to use acceptable birth control measures during the first 3 weeks after vaccination.

• Have immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months.

• Have an active neoplastic disease or a history of any hematologic malignancy.

• Have long-term use of glucocorticoids including oral, parenteral or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months. (Nasal and topical steroids are allowed).

• Have a history of receiving immunoglobulin or other blood product within the 3 months prior to vaccination in this study.

• Have known active human immunodeficiency virus (HIV) infection, acute hepatitis B or C infection, autoimmune hepatitis and related cirrhosis

• Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. Unwilling to refuse participation in another clinical study through the end of this study.

• History of progressive or severe neurological disorders

• Have received any licensed vaccines within 4 weeks or inactivated licensed vaccines within 2 weeks prior to vaccination in this study or plan receipt of such vaccines within 21 days following the second vaccination (only exception being unadjuvanted seasonal influenza vaccines which are allowed until 1 week prior to and after 1 week study vaccinations).

• Axillary temperature = 38°C or oral temperature = 38.5°C within 3 days of intended study vaccination

• Surgery planned during the study period that in the Investigator's opinion would interfere with the study visits schedule

• Have a history of alcohol or drug abuse in the last 5 years.

• Have a history of Guillain-Barré Syndrome.

• Have any condition that the investigator believes may interfere with successful completion of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Chronic Disease
• Chronic Illness

Intervention

Biological:
• influenza vaccine
single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine

Drug:
• Imiquimod
pretreatment with topical imiquimod cream to the injection site before vaccination

Biological:
• influenza vaccine
single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine

Drug:
• Aqueous cream
pretreatment with topical aqueous cream to the injection site before vaccination

Biological:
• influenza vaccine
single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine

Drug:
• Aqueous cream
pretreatment with topical aqueous cream to the injection site before vaccination

Locations

Country	Name	City	State
Hong Kong	The University of Hong Kong, Queen Mary Hospital	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroconversion rate	The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of =40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination on day 7	day 7	No
Secondary	Geometric mean titer old increase in influenza antibody titer	The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assays on day 21 compared to day 0	day 21	No
Secondary	Seroprotection rate	The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay on day 21	day 21	No
Secondary	Adverse events (Immediate)	Patients who develop systemic or local adverse events within 30 minutes of vaccination	30 minutes after vaccination	Yes
Secondary	Geometric mean titer old increase in influenza antibody titer	The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay on day 7 compared to day 0	day 7	No
Secondary	Seroprotection rate	The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay on day 7	day 7	No
Secondary	Geometric mean titer old increase in influenza antibody titer	The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay at year 1 compared to day 0	year 1	No
Secondary	Seroprotection rate	The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay at year 1	year 1	No
Secondary	Seroconversion rate	The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of =40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination at year 1	Year 1	No
Secondary	Adverse events (7 days)	Patients who develop systemic or local adverse events within 1 week of vaccination	7 days after vaccination	Yes
Secondary	Seroconversion rate	The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of =40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination on day 21	Day 21	No
Secondary	Geometric mean titer old increase in influenza antibody titer	The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay at year 1 compared to day 0	Day 14	No
Secondary	Seroprotection rate	The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay at year 1	Day 14	No
Secondary	Seroconversion rate	The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of =40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination at year 1	Day 14	No
Secondary	Effectiveness	hospitalization for pneumonia or influenza	1 year post vaccination	No
Secondary	Effectiveness	Nasopharyngeal sample positive for influenza A	1 year post vaccination	No